Shares of the Neuropharm Group Plc remained weak at sharply lower levels following news that its Phase 3 trial of a treatment for autism failed to show efficacy. The preliminary trial results were announced on 18 February 2009. ---Subscribe to MedNous to access this article--- Company News
